New federal board gets binding veto over risky life sciences research funding
H.R. 1864 — Risky Research Review Act · Filed by H. Griffith (R-VA) · Introduced Mar 5, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new independent federal agency called the Life Sciences Research Security Board to review and approve all federal funding for high-risk life sciences research before money is awarded. The Board—composed of 9 scientists, national security experts, and biosafety specialists—has binding authority to block, approve, or impose safety conditions on research involving dangerous pathogens or gain-of-function experiments. Researchers and federal agencies must attest to whether their work is high-risk, and the Board can audit past and ongoing research to ensure compliance.
Why we flagged it
The bill's core mechanism is the creation of a binding pre-award review board for high-risk life sciences research. It is fundamentally a regulatory gatekeeping and safety-review instrument, not a deregulation or subsidy. The Board's authority is narrow but absolute: it can only approve, block, or condition funding for research meeting statutory definitions of high-risk work.
What the text implies
- The Board's definition of 'high-risk life sciences research' is expansive and includes any research the Board itself votes to add to the category by Federal Register notice, creating open-ended regulatory scope that can grow without new legislation.
- Researchers must pause work within 24 hours of identifying a change in circumstances that might make ongoing research high-risk, creating operational friction and potential liability for honest disclosure of research evolution.
The full analysis lists 5 implications of this text.
Who it affects
The Board creates an independent safety checkpoint for federally funded research with pandemic or bioweapon potential, reducing the risk that dangerous research proceeds without expert biosecurity review. Citizens benefit from binding oversight of gain-of-function and dual-use pathogen research, which poses catastrophic public health and national security risks.